It May Be Possible to Predict Recurrence of Mesothelioma with Help from AI

predict recurrence of mesothelioma

A newly-published report suggests that artificial intelligence (AI) might help pathologists predict recurrence of mesothelioma. The report focuses on technology developed by the RIKEN Center for Advanced Intelligence Project (AIP) in Japan. The Center claims the computer program taught itself to recognize key features in images of cancer.  Some of the features were ones that even pathologists did not know about. The findings suggest that AI and pathologists could predict recurrence of mesothelioma better than pathologists alone.  How AI Might Predict Recurrence of Mesothelioma  A computer program usually has to be “taught” to perform a certain task. But this limits how far the learning can go. Instead of “teaching” it about cancer, researchers let the RIKEN technology learn on its … Continue reading It May Be Possible to Predict Recurrence of Mesothelioma with Help from AI »

Protein Biomarker for Mesothelioma Linked to Shorter Survival

protein biomarker for mesothelioma

An international team of scientists has identified a protein biomarker for mesothelioma that appears to shorten survival. The biomarker is CD70. It belongs to the tumor necrosis factor (TNF) family of proteins. New research suggests that patients who express more of this protein biomarker for mesothelioma have faster-growing tumors that are less likely to respond to treatment. High CD70 levels have been linked with tumor aggression in some other types of cancer. This is the first time they have been linked to malignant pleural mesothelioma survival.  CD70 and Mesothelioma Prognosis Pleural mesothelioma is a highly aggressive type of tumor. It grows on the membranes around internal organs. Mesothelioma rarely responds to standard cancer treatments. People diagnosed with pleural mesothelioma are … Continue reading Protein Biomarker for Mesothelioma Linked to Shorter Survival »

Tracking Mesothelioma Recurrence: FDG-PET/CT Versus CT

mesothelioma recurrence

FDG-PET/CT may be a more effective way to track malignant pleural mesothelioma recurrence than contrast-enhanced CT scanning.  That is the conclusion of cancer researchers with Japan’s Hyogo College of Medicine. The researchers focused on fifty patients who underwent radical surgery for pleural mesothelioma. Afterwards, doctors used both FDG-PET/CT and contrast-enhanced CT scans to track mesothelioma progression. Two experienced examiners assessed the cases. They concluded that FDG-PET/CT was more accurate than CT for diagnosing mesothelioma recurrence. Mesothelioma Recurrence After Surgery Pleural mesothelioma is one of the most difficult cancers to treat. It arises in the layers of the pleural membrane that surrounds the lungs. Mesothelioma tumors tend to grow and spread quickly. Treatments like chemotherapy, surgery, and radiotherapy can sometimes slow … Continue reading Tracking Mesothelioma Recurrence: FDG-PET/CT Versus CT »

Drinking and Mesothelioma Risk: How Much is Too Much?

drinking and mesothelioma risk

The findings of a major new study on cancer and alcohol suggest there may be an even stronger link between drinking and mesothelioma risk than previously thought. The Japanese study included more than 120,000 drinkers and non-drinkers. It tracked which participants got any type of cancer over a 15 year period. Cancer diagnoses were correlated with participants’ drinking habits.  The report found that even light drinkers faced a higher incidence of cancers like malignant mesothelioma. It is one of the largest studies to connect cancer incidence, drinking and mesothelioma risk.  Even Light to Moderate Drinkers Face Risk Scientists have known about the connection between drinking and mesothelioma risk for some time. But the problem of alcohol consumption and cancer had … Continue reading Drinking and Mesothelioma Risk: How Much is Too Much? »

Peritoneal Mesothelioma Surgery with HIPEC Can Trigger Blood Cell Problems

peritoneal mesothelioma surgery with HIPEC

More than half of patients who have peritoneal mesothelioma surgery with HIPEC develop problems with their blood cells afterward. That’s the finding of a team of cancer researchers from Singapore.  The group analyzed 15 years worth of data on peritoneal mesothelioma surgery outcomes. They found that, even though the procedure saves lives, it can be risky.  Older patients and those who had prior chemotherapy were most likely to develop hematological toxicities after peritoneal mesothelioma surgery.  Hematological Toxicities and Mesothelioma Treatment Hematological toxicities are problems with the cells that make up the blood. This can include white blood cells, red blood cells, platelets, and proteins involved in bleeding and clotting.  Several drugs that kill mesothelioma cells can cause blood cell problems. … Continue reading Peritoneal Mesothelioma Surgery with HIPEC Can Trigger Blood Cell Problems »

Repeated Mesothelioma Surgeries Credited with Japanese Man’s Survival

repeated mesothelioma surgeries

Can repeated mesothelioma surgeries extend peritoneal mesothelioma survival? A new case report out of Japan suggests the answer may be yes.  The article recounts the case of a patient with peritoneal mesothelioma. Each time surgeons removed a mesothelioma tumor, a new one would occur in a different location.  The man had four separate mesothelioma surgeries over the course of five years.  Repeated mesothelioma surgeries are not the norm. But this treatment approach may be the reason for the man’s unusually long mesothelioma survival.  Surgical Treatment of Peritoneal Mesothelioma Peritoneal mesothelioma accounts for about 20 percent of mesothelioma cases in the US each year. It occurs on the membrane that surrounds the abdominal organs. Because it sits so close to these … Continue reading Repeated Mesothelioma Surgeries Credited with Japanese Man’s Survival »

Signs of Peritoneal Mesothelioma After Radiotherapy

signs of peritoneal mesothelioma after radiotherapy

Japanese researchers are reminding doctors to watch for signs of peritoneal mesothelioma in people who have undergone past radiotherapy.  Many cancer patients undergo radiotherapy. Radiation disrupts the DNA inside cancer cells. This can help keep these malignant cells from replicating and spreading.  But radiation treatment also has a downside. It can cause cellular changes in healthy cells, too. This can cause side effects right away, or decades later.  As more people have radiation and survive, scientists at the Shinshu University School of Medicine say more of them could develop radiation-related mesothelioma later in life. But the signs of peritoneal mesothelioma years after radiation are easy to miss. Peritoneal Mesothelioma Case Study The new report is based on the case of … Continue reading Signs of Peritoneal Mesothelioma After Radiotherapy »

Mesothelioma Tumor Response to Nivolumab Detailed in New Case Study

mesothelioma tumor response to nivolumab

An Indian woman in still alive two years after a mesothelioma diagnosis thanks to a remarkable mesothelioma tumor response to nivolumab. Nivolumab is sold under the brand name Opdivo. It is a type of immunotherapy. Nivolumab is sometimes used for lung cancer that progresses after chemotherapy. A hospital in Mumbai tried nivolumab on a pleural mesothelioma patient after several types of chemotherapy did not work. Doctors say the mesothelioma tumor response to nivolumab was so great that the patient no longer needed supplemental oxygen.  Opdivo in Mesothelioma Treatment Opdivo is not FDA-approved for mesothelioma treatment. Only Alimta (pemetrexed) holds that designation. But pleural mesothelioma grows quickly and is hard to treat. Even the gold standard therapies often do not work … Continue reading Mesothelioma Tumor Response to Nivolumab Detailed in New Case Study »

First-Line Chemotherapy for Peritoneal Mesothelioma

chemotherapy for peritoneal mesothelioma

The same drugs doctors use to treat pleural mesothelioma can provide effective chemotherapy for peritoneal mesothelioma, too. Japanese researchers reviewed the cases of 29 peritoneal mesothelioma patients. These patients had first-line treatment with cisplatin and pemetrexed between 2001 and 2016. The results suggest these drugs are safe and potent chemotherapy for peritoneal mesothelioma. The finding may help doctors and patients make better treatment decisions. Treating Malignant Mesothelioma Malignant mesothelioma is a membrane cancer. It usually occurs in one of two places. About 80 percent of mesothelioma tumors arise on the membrane that surrounds the lungs (the pleura). This is called pleural mesothelioma.  About 20 percent of the 2,500 cases of mesothelioma diagnosed in the US each year are peritoneal. Peritoneal … Continue reading First-Line Chemotherapy for Peritoneal Mesothelioma »

Experimental Mesothelioma Treatment Targets Tumor Growth Compounds

Experimental mesothelioma treatment

Hong Kong researchers have released the first results of an experimental mesothelioma treatment they are working on. The treatment targets organic compounds believed to contribute to mesothelioma growth. The trial took place at the University of Hong Kong. Mice with mesothelioma received doses of an enzyme inhibitor called DFMO. The drug appears to stop the production of organic compounds called polyamines. In tests, mice with lower polyamine levels lived longer with pleural mesothelioma. Enzymes Contribute to Tumor Growth The growth and spread of pleural mesothelioma is a complex process. It involves many different proteins and enzymes working together. Scientists have not yet identified all of the compounds that contribute to cancer growth. But the experimental mesothelioma treatment in Hong Kong … Continue reading Experimental Mesothelioma Treatment Targets Tumor Growth Compounds »

Get your free copy of
“Surviving Mesothelioma” Today!